pancreatic-cancer
Predicting lymph node metastasis (LNM) in pancreatic ductal adenocarcinoma (PDAC) before surgery from CT scans is difficult due to low sensitivity and inter-institutional heterogeneity. This retrospective multi-center study of 546 patients (3 institutions) developed a federated deep learning…
pancreatic-cancer
IL-12 is a potent immunostimulatory cytokine with anti-cancer potential, but systemic administration causes severe toxicities (cytokine release syndrome, multi-organ dysfunction). This review covers delivery platforms addressing this: cellular encapsulation, virotherapy, lipid nanocapsules,…
pancreatic-cancer
A series of ferrocene-pyrazole hybrid compounds were tested against pancreatic cancer (BxPC-3). Compound 11 showed superior anti-cancer effects and low toxicity to normal HK-2 cells, with low hemolytic activity. Proteomics and metabolomics revealed 35 proteins and 58 metabolites with significantly…
pancreatic-cancer
Single-cell transcriptomics + functional TCR characterization in murine pancreatic cancer found substantial diversity of tumor-reactive TCR clonotypes. Most reactive TCRs recognized syngeneic tumors across tissue types. Three T cell epitope classes were identified: a neoantigen, an endogenous…
pancreatic-cancer
Alkaliptosis is a pH-dependent cell death mechanism driven by JTC801 that disrupts intracellular pH homeostasis. Because it is mechanistically distinct from apoptosis, cells resistant to standard treatments remain susceptible. Particularly effective against pancreatic ductal adenocarcinoma. This…
pancreatic-cancer
CECMS combines CbAgo (which eliminates wild-type DNA) with CRISPR-Cas12a (which detects enriched mutant alleles) to achieve 100-fold higher sensitivity than conventional Cas12a biosensors, detecting VAFs as low as 0.01%. In undiluted human serum, it detected KRAS G12D mutations at 0.1% VAF.
pancreatic-cancer
Follow-up of 35 patients with serous cystadenomas over 32 months found no malignant transformation and no association between initial lesion size and subsequent growth rate. Both large (>4 cm) and small SCAs grew equally, challenging the ACR recommendation for surgical consultation in large…
pancreatic-cancer
CA19-9 is the most commonly used blood biomarker for pancreatic cancer, elevated in most patients and used to monitor disease progression. But this study reveals that CA19-9 isn't merely a passive indicator — it actively promotes liver metastasis.
pancreatic-cancer
Pancreatic ductal adenocarcinoma (PDAC) is typically stratified into 'basal-like' and 'classical' molecular subtypes, which carry different prognoses. But histological morphology — what the tumor looks like under a microscope — also varies significantly and may carry independent information.
pancreatic-cancer
Repeated tumor ablation trains the immune system to attack pancreatic cancer — and reveals a targetable brake Thermal ablation (using heat to destroy tumors) is gaining use in pancreatic cancer, but it has mostly been viewed as a local treatment. This study tested whether repeated radiofrequency ablation could trigger a systemic
pancreatic-cancer
Newly identified cancer-associated fibroblast subtype could predict who responds to pancreatic cancer treatment Pancreatic ductal adenocarcinoma (PDAC) is notorious for its dense, fibrous tumor stroma — a barrier that blocks drug delivery and suppresses immune responses. Within this stroma, cancer-associated fibroblasts (CAFs) play complex, sometimes opposing roles. Using single-cell RNA sequencing
pancreatic-cancer
Blood test using tumor DNA epigenetics can non-invasively classify pancreatic cancer subtypes that predict treatment response Pancreatic cancer (PDAC) comes in two major subtypes — classical and basal-like — that have very different prognoses and respond differently to chemotherapy and RAS inhibitors. Until now, determining subtype required a tissue biopsy, which is